According to the article by Weissgerber et al., titled “Preeclampsia and diabetes,” in developed countries, Preeclampsia affects 2–7% of pregnancies in non-diabetic women. As per a study conducted by Leon et al., titled “Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records,” out of 1.3 million participants, 2.24% had at least one diagnosis of Preeclampsia.
DelveInsight's "Preeclampsia Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Preeclampsia Market, historical and forecasted epidemiology, the pipeline insight as well as the Preeclampsia market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Preeclampsia market report also covers emerging drugs, current treatment practices, Preeclampsia market shares of the individual therapies, current and forecasted Preeclampsia Market Size segmented by seven major markets. The report provides a detailed current Preeclampsia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Preeclampsia Market Growth Analysis
The key drivers for the Preeclampsia market is an increase in the risk factors of Preeclampsia such as obesity, diabetes, hypertension, and an increasing incidence of PE.
The Preeclampsia market analysis section of the report helps to build a detailed comprehension of the historic, current, and forecasted Preeclampsia market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
Preeclampsia Epidemiology Forecast
The Preeclampsia epidemiology section covers insights about historical and current Preeclampsia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Preeclampsia Pipeline Analysis
The Preeclampsia Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Preeclampsia market or expected to get launched in the market during the study period. The analysis covers the Preeclampsia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.
Some of the key companies in the Preeclampsia market includes:
AMAG Pharmaceuticals
Kyowa Kirin Co., Ltd
Glenveigh Medical
VG Life Science
APP Pharmaceuticals (Fresenius Kabi USA)
And many others.
Preeclampsia Therapies Covered in the report includes AMAG-423 (digoxin immune fab), KW-3357, VG1177, and others.
Source: Preeclampsia Market Growth